Pharmafile Logo
Pharmafocus logo
Advanced Search

Genzyme

Showing 15 posts of 98 posts found.

Sanofi submits key MS pill for approval

June 12, 2012
Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi

Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …

News
Genzyme image

Genzyme boosts capacity following green light for Waterford plant

May 8, 2012
Manufacturing and Production EMA, FDA, Genzyme, Sanofi, Waterford

Sanofi subsidiary Genzyme has doubled its capacity to fill-and-finish two of its drugs for rare disorders following approval of a …

News

Pfizer enters Gaucher disease market

May 3, 2012
Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv

Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso.  Elelyso (taliglucerase alfa) is an enzyme replacement therapy …

News
Shire's Vpriv website

Shire’s Vpriv website in breach of ABPI Code

April 24, 2012
Medical Communications, Sales and Marketing ABPI, Genzyme, PMCPA, Shire, Vpriv, code

Shire’s website for its Gaucher’s disease drug Vpriv has fallen foul of the ABPI’s Code of Conduct.  The complaint was …

News
Genzyme Framingham image

Genzyme starts shipping Fabrazyme from Framingham facility

March 6, 2012
Manufacturing and Production Fabrazyme, Framingham, Genzyme

Sanofi subsidiary Genzyme has shipped the first supplies of Fabry disease treatment Fabrazyme produced at its new plant in Framingham, …

News
Rare Disease Day

‘Rare Disease Day’ highlights need for research

February 29, 2012
Research and Development, Sales and Marketing Genzyme, Rare Disease Day, Shire

 Today has been designated as Rare Disease Day around the world, with researchers, regulators and the industry all raising awareness …

News

EMA accepts Genzyme MS drug for review

February 24, 2012
Research and Development, Sales and Marketing EMA, Genzyme, Sanofi, teriflunomide

The European Medicines Agency has accepted Genzyme’s application for its multiple sclerosis pill teriflunomide.  Genzyme, which is wholly owned by …

News
Genzyme picture

Genzyme to close UK site

February 24, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, UK, job cuts

Genzyme will close its Cambridge R&D site by the end of the year, with a loss of around 60 jobs.  …

News
Genzyme picture

Genzyme’s Framingham site cleared by FDA

January 24, 2012
Manufacturing and Production FDA, Fabrazyme, Fabry, Genzyme

The FDA has cleared Genzyme to begin production of Fabrazyme at its new manufacturing site. The approval of the new …

News

Genzyme lifted by EU approval of Fabrazyme facility

January 20, 2012
Manufacturing and Production Boston, EMA, Fabrazyme, Genzyme

Sanofi subsidiary Genzyme moved a crucial step closer to resolving its long-standing manufacturing problems after the European Medicines Agency gave …

News

Genzyme appoints new leaders for multiple sclerosis and rare disease businesses

November 14, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genzyme

Genzyme, a Sanofi company, has appointed William Sibold as head of multiple sclerosis and Rogério Vivaldi as head of rare …

Appointment

David Meeker appointed as chief executive of Genzyme

October 25, 2011
Research and Development, Sales and Marketing Genzyme, Sanofi

Sanofi has appointed David Meeker as chief executive of its new biotech acquisition Genzyme. He will report to Christopher Viehbacher, …

Appointment

Genzyme completes expansion at Waterford plant

October 14, 2011
Manufacturing and Production Genzyme, Sanofi

Sanofi’s Genzyme unit has officially opened a €150 million expansion at its ten-year-old biotechnology facility in Waterford, Ireland that will …

News
Genzyme

Genzyme confirms further Fabrazyme delay

September 13, 2011
Manufacturing and Production Fabrazyme, Genzyme, pharma manufacturing news

Genzyme has been forced to delay shipments of its Fabry disease treatment Fabrazyme once again, blaming its “quality release process”. …

News

Sanofi banks on personalised medicine for growth

September 8, 2011
Sales and Marketing Genzyme, Sanofi

Sanofi has nailed its colours to the mast of personalised medicine, banking on the purchase of US biotech company Genzyme, …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026